We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Researchers Seek Disease Biomarkers Hidden in the Long Noncoding RNA Segment of the Genome

By LabMedica International staff writers
Posted on 01 Feb 2015
Print article
Researchers have analyzed the large segment of DNA in the human genome that underlies the species of nucleic acids called long noncoding RNAs (lncRNA), a genre that functions as important regulators of tissue physiology and disease processes including cancer.

To delineate genome-wide lncRNA expression, investigators at the University of Michigan (Ann Arbor, USA) evaluated 7,256 RNA sequencing (RNA-seq) libraries from tumors, normal tissues, and cell lines comprising over 43 terabytes of nucleotide sequence from 25 independent studies.

Evaluation of this data set, as described in the January 19, 2015, online edition of the journal Nature Genetics, yielded a consensus human transcriptome of 91,013 expressed genes. Over 68% (58,648) of genes were classified as coding for lncRNAs, of which 79% were previously unannotated. About 1% (597) of the lncRNAs harbored ultraconserved elements, and 7% (3,900) overlapped disease-associated SNPs (single nucleotide polymorphisms). The complete dataset, named the MiTranscriptome compendium, has been made available to the scientific community online (Please see Related Links below).

To prioritize lineage-specific, disease-associated lncRNA expression, the investigators employed nonparametric differential expression testing and nominated 7,942 lineage- or cancer-associated lncRNA genes. One lncRNA, SChLAP1, was identified as a potential biomarker for aggressive prostate cancer. This RNA was more highly expressed in metastatic prostate cancer than in early stage disease and was found primarily in prostate cancer cells, not in other cancers or normal cells.

"Some long non-coding RNAs tend to be exquisitely specific for cancer, while protein-coding genes are often not. That is what makes lncRNAs a very promising target for developing biomarkers," said senior author Dr. Arul M. Chinnaiyan, professor of pathology at the University of Michigan. "We hope that researchers will investigate the MiTransciptome compendium and begin to nominate lncRNAs for further study and development. It is likely that only a subset of these has true function but as a previously untapped area, it holds great promise. We know about protein-coding genes, but that represents only 1%–2% of the genome. Much less is known about the biology of the noncoding genome in terms of how it might function in a human disease like cancer."

Related Links:

University of Michigan
MiTranscriptome


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.